Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

NIH registered a new observational clinical trial on ClinicalTrials.gov studying three biomarkers—GFAP, NfL, and VEGF—in patients with progressive multiple sclerosis. The study seeks to determine whether these biomarkers can serve as reliable indicators of disease progression, potentially aiding in treatment decisions and understanding MS pathophysiology.

For healthcare providers and clinical researchers, this registry entry represents informational documentation of ongoing MS biomarker research. It does not create new compliance obligations or regulatory requirements. Clinical investigators conducting MS-related research should maintain awareness of evolving biomarker studies and ensure proper registration of their own clinical trials on ClinicalTrials.gov in accordance with applicable registration requirements.